Human Babesiosis in Metropolitan France

Human Babesiosis in Metropolitan France: a Retrospective and Multicenter Descriptive Analysis.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07345988

Acronym

BABERETRO

Enrollment

100

Registered

2026-01-16

Start date

2025-11-04

Completion date

2027-05-04

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Babesiosis

Keywords

Human Babesiosis

Brief summary

Human babesiosis is a rare zoonosis in Europe caused by protozoa of the genus Babesia, transmitted to humans mainly by ticks of the genus Ixodes. The infection mainly affects individuals who have undergone splenectomy, are immunocompromised, or are elderly, which correspond to the risk factors for the disease. The infection is often underdiagnosed due to its rarity and its often nonspecific clinical presentation (asthenia, fever, flu-like syndrome). In these high-risk patients in particular, the infection can progress to severe forms, with a mortality rate of up to 20-40%. The clinical picture is then that of a severe infection with multiple organ failure: multifactorial renal failure, respiratory distress due to lesion edema, and disseminated intravascular coagulation. One of the main obstacles to understanding human babesiosis in France and Europe is the low number of cases recorded and published. This situation limits knowledge about the epidemiology of the disease, its clinical presentations, its potential severity, and the effectiveness of the treatments used. The aim of this study is to describe the epidemiological, clinical, biological, therapeutic, and prognostic characteristics of human babesiosis cases diagnosed in metropolitan France.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult subjects (≥18 years old) * With a diagnosis of babesiosis confirmed by blood smear or PCR * Treated in associated centers during the period from January 1, 2000, to December 31, 2024

Exclusion criteria

\- Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Description of the epidemiological, clinical, biological, and therapeutic characteristics of human babesiosis cases diagnosed in mainland France.	Up to 18 months	This study does not include any evaluation; it simply describes the epidemiological, clinical, biological, and therapeutic characteristics of human babesiosis cases diagnosed in mainland France.

Countries

France

Contacts

Primary ContactVictor GERBER, MD

victor.gerber@chru-strasbourg.fr33 3 68 85 37 97

Outcome results